Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 12/2016

24.03.2016 | Original Paper

Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators

verfasst von: Maxim Polonsky, Julia Rozanova, Lyuba Azbel, Chethan Bachireddy, Jacob Izenberg, Tetiana Kiriazova, Sergii Dvoryak, Frederick L. Altice

Erschienen in: AIDS and Behavior | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

In this study, we use data from a survey conducted in Ukraine among 196 HIV-infected people who inject drugs, to explore attitudes toward drug addiction and methadone maintenance therapy (MMT), and intentions to change drug use during incarceration and after release from prison. Two groups were recruited: Group 1 (n = 99) was currently incarcerated and Group 2 (n = 97) had been recently released from prison. This paper’s key finding is that MMT treatment and addiction recovery were predominantly viewed as mutually exclusive processes. Group comparisons showed that participants in Group 1 (pre-release) exhibited higher optimism about changing their drug use, were less likely to endorse methadone, and reported higher intention to recover from their addiction. Group 2 participants (post-release), however, reported higher rates of HIV stigma. Structural equation modeling revealed that in both groups, optimism about recovery and awareness of addiction mediated the effect of drug addiction severity on intentions to recover from their addiction.
Literatur
1.
2.
3.
4.
MoHo Ukraine. Ukraine harmonised AIDS response progress report. Kyiv: Ministry of Health of Ukraine; 2012.
5.
Čakalo JI, Božičević I, Vitek C, Mandel JS, Salyuk T, Rutherford GW. Misclassification of men with reported HIV infection in Ukraine. AIDS Behav. 2015;19(10):1938–40.CrossRefPubMed
6.
Petersen Z, Myers B, van Hout MC, Pluddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J. 2013;10:13.CrossRefPubMedPubMedCentral
7.
Bobrovskyy O, Eschenko O, Havovych Y, Kobyschcha Y. Ukraine harmonized AIDS response progress report. Kyiv: International HIV/AIDS Alliance; 2012.
8.
9.
Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One. 2013;8(3):e59643.CrossRefPubMedPubMedCentral
10.
Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Correlates of HIV infection and being unaware of HIV status among soon-to-be-released Ukrainian prisoners. J Int AIDS Soc. 2014;17(1):19005.CrossRefPubMedPubMedCentral
11.
Azbel L, Wickersham JA, Wegman MP, Polonsky M, Suleymanov M, Ismayilov R, et al. Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. Drug Alcohol Depend. 2015;151:68–75.CrossRefPubMedPubMedCentral
12.
Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321–9.CrossRefPubMed
13.
Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2008(2):CD002207.
14.
Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8(3):e1000423.CrossRefPubMedPubMedCentral
15.
Kim SW, Pulkki-Brannstrom AM, Skordis-Worrall J. Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine. Cost Eff Resour Alloc C/E. 2014;12:25.CrossRefPubMed
16.
Hedrich D, Alves P, Farrell M, Stover H, Moller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–17.CrossRefPubMed
17.
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277–85.CrossRefPubMedPubMedCentral
18.
Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–9.CrossRefPubMedPubMedCentral
19.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.CrossRefPubMedPubMedCentral
20.
MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34–52.CrossRefPubMed
21.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.CrossRefPubMedPubMedCentral
22.
Sarang A, Stuikyte R, Bykov R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007;18(2):129–35.CrossRefPubMed
23.
Torrens M, Fonseca F, Castillo C, Domingo-Salvany A. Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bull World Health Organ. 2013;91(2):136–41.CrossRefPubMedPubMedCentral
24.
Zaller N, Mazhnaya A, Larney S, Islam Z, Shost A, Prokhorova T, et al. Geographic variability in HIV and injection drug use in Ukraine: Implications for integration and expansion of drug treatment and HIV care. Int J Drug Policy. 2015;26(1):37–42.CrossRefPubMed
25.
Degenhardt L, Mathers BM, Wirtz AL, Wolfe D, Kamarulzaman A, Carrieri MP, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy. 2014;25(1):53–60.CrossRefPubMed
26.
Polonsky M, Azbel L, Wickersham JA, Taxman FS, Grishaev E, Dvoryak S, et al. Challenges to implementing opioid substitution therapy in Ukrainian prisons: personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend. 2015;148:47–55.CrossRefPubMed
27.
Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9(1):57–66.CrossRefPubMed
28.
29.
Oser CB, Knudsen HK, Staton-Tindall M, Taxman F, Leukefeld C. Organizational-level correlates of the provision of detoxification services and medication-based treatments for substance abuse in correctional institutions. Drug Alcohol Depend. 2009;103(Suppl 1):S73–81.CrossRefPubMed
30.
Taxman FS, Cropsey KL, Melnick G, Perdoni ML. COD services in community correctional settings: an examination of organizational factors that affect service delivery. Behav Sci Law. 2008;26(4):435–55.CrossRefPubMed
31.
Taxman FS, Henderson CE, Belenko S. Organizational context, systems change, and adopting treatment delivery systems in the criminal justice system. Drug Alcohol Depend. 2009;103:S1–6.CrossRefPubMed
32.
Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manag. 2008;4(2):81–6.PubMedPubMedCentral
33.
McKenzie M, Nunn A, Zaller ND, Bazazi AR, Rich JD. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag. 2009;5(4):219–27.PubMedPubMedCentral
34.
Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine–programme description and policy implications. Int J Drug Policy. 2007;18(4):326–8.CrossRefPubMedPubMedCentral
35.
Kraus SJ. Attitudes and the prediction of behavior: a meta-analysis of the empirical literature. Pers Soc Psychol Bull. 1995;21(1):58–75.CrossRef
36.
Pomery EA, Gibbons FX, Reis-Bergan M, Gerrard M. From willingness to intention: experience moderates the shift from reactive to reasoned behavior. Pers Soc Psychol Bull. 2009;35(7):894–908.CrossRefPubMedPubMedCentral
37.
Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Brown BS. Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts. Drug Alcohol Depend. 2011;115(1–2):23–9.CrossRefPubMed
38.
Morozova O, Azbel L, Grishaev Y, Dvoryak S, Wickersham JA, Altice FL. Ukrainian prisoners and community reentry challenges: implications for transitional care. Int J Prison Health. 2013;9(1):5–19.CrossRefPubMedPubMedCentral
39.
Choi P, Kavasery R, Desai MM, Govindasamy S, Kamarulzaman A, Altice FL. Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia. Int J STD AIDS. 2010;21(6):416–23.CrossRefPubMedPubMedCentral
40.
Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy. 2014;25(5):845–52.CrossRefPubMedPubMedCentral
41.
Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133(1):154–60.CrossRefPubMedPubMedCentral
42.
Bullinger M, Alonso J, Apolone G, Leplege A, Sullivan M, Wood-Dauphinee S, et al. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):913–23.CrossRefPubMed
43.
Brislin RW. Back-translation for cross-cultural research. J Cross Cult Psych. 1970;1:185–216.CrossRef
44.
Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015;21(1):12–26.CrossRefPubMedPubMedCentral
45.
Nilssen O, Averina M, Brenn T, Brox J, Kalinin A, Archipovski V. Alcohol consumption and its relation to risk factors for cardiovascular disease in the north-west of Russia: the Arkhangelsk study. Int J Epidemiol. 2005;34(4):781–8.CrossRefPubMed
46.
Uuskula A, Laisaar KT, Raag M, Amico KR, Sharma A, DeHovitz J. Antiretroviral therapy (ART) adherence and correlates to non-adherence among people on ART in Estonia. AIDS Care. 2012;24(12):1470–9.CrossRefPubMed
47.
Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the multidimensional scale of perceived social support. J Pers Assess. 1990;55(3–4):610–7.CrossRefPubMed
48.
Canty-Mitchell J, Zimet GD. Psychometric properties of the Multidimensional Scale of Perceived Social Support in urban adolescents. Am J Community Psychol. 2000;28(3):391–400.CrossRefPubMed
49.
Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.CrossRefPubMed
50.
51.
McKee KJ, Markova I, Power KG. Concern, perceived risk and attitudes towards HIV/AIDS in Scottish prisons. AIDS Care. 1995;7(2):159–70.CrossRefPubMed
52.
Forste R, Clarke L, Bahr S. Staying out of trouble: intentions of young male offenders. Int J Offender Ther Comp Criminol. 2011;55(3):430–44.CrossRefPubMed
53.
Dhami MK, Mandel DR, Loewenstein G, Ayton P. Prisoners’ positive illusions of their post-release success. Law Hum Behav. 2006;30(6):631–47.CrossRefPubMed
54.
Preacher KJ, Rucker DD, Hayes AF. Addressing moderated mediation hypotheses: theory, methods, and prescriptions. Multivar Behav Res. 2007;42:185–227.CrossRef
55.
Bollen KA, Stine RA. Bootstrapping goodness-of-fit measures in structural equation models. Sociol Methods Res. 1992;21(2):205–29.CrossRef
56.
Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8.CrossRefPubMedPubMedCentral
57.
Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–9.CrossRefPubMedPubMedCentral
58.
Stöver H. HIV/AIDS prevention care, treatment and support in prision setting. A framework for and effective national response. In: United Nations Office on Drugs and Crime/World Health Organization, Geneva; 2006.
59.
United Nations Office on Drugs and Crime (UNODC). Drug dependence treatment: interventions for drug users in prison. Vienna, Austria: TreatNet, 2012 Contract No.: GLO/H43.
60.
61.
Goffman E. Stigma: notes on the management of spoiled identity. Englewood Cliffs: Prentice-Hall; 1963.
62.
Festinger L. A theory of social comparison processes. Hum Relat. 1954;7:117–42.CrossRef
63.
Comfort M. Doing time together: love and family in the shadow of the prison. Chicago: University of Chicago Press; 2009.
64.
Harding DJ, Wyse JJ, Dobson C, Morenoff JD. Making ends meet after prison. J Policy Anal Manag. 2014;33(2):440–70.CrossRef
65.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.CrossRefPubMed
66.
Bojko MJ, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z, et al. Bureaucracy & beliefs: assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs. 2015;22(3):255–62.PubMedPubMedCentral
67.
Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy. 2014;25(5):845–52.CrossRefPubMedPubMedCentral
68.
Bryan A, Schmiege SJ, Broaddus MR. Mediational analysis in HIV/AIDS research: estimating multivariate path analytic models in a structural equation modeling framework. AIDS Behav. 2007;11(3):365–83.CrossRefPubMed
69.
Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58.CrossRefPubMed
70.
Culbert GJ, Bazazi AR, Waluyo A, Murni A, Muchransyah AP, Iriyanti M, et al. The influence of medication attitudes on utilization of antiretroviral therapy (ART) in indonesian prison. AIDS Behav. 2015:1–13.
71.
Culbert GJ, Earnshaw VA, Wulanyani NM, Wegman MP, Waluyo A, Altice FL. Correlates and experiences of HIV stigma in prisoners living with HIV in Indonesia: a mixed-method analysis. J Assoc Nurses AIDS Care. 2015;26(6):743–57.CrossRefPubMedPubMedCentral
72.
Izenberg J, Altice FL. Next steps for Ukraine—abolition of HIV registries, implementation of routine HIV testing and expansion of services. Addiction. 2010;105(3):569–70.CrossRefPubMedPubMedCentral
73.
Bojko MJ, Dvoriak S, Altice FL. At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine. Addiction. 2013;108(10):1697–9.CrossRefPubMedPubMedCentral
74.
Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133(1):154–60.CrossRefPubMedPubMedCentral
75.
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-V). 5th ed. 5Washington, DC: American Psychiatric Association; 2013.CrossRef
76.
Gordon MS, Kinlock TW, Miller PM. Medication-assisted treatment research with criminal justice populations: challenges of implementation. Behav Sci Law. 2011;29(6):829–45.CrossRefPubMedPubMedCentral
77.
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40.CrossRefPubMed
78.
Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59–65.CrossRefPubMed
79.
Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820–8.CrossRefPubMed
80.
Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions. J Acquir Immune Defic Syndr. 2015;69:S155–61.CrossRefPubMedPubMedCentral
81.
Meyer JP, Cepeda J, Taxman FS, Altice FL. Sex-related disparities in criminal justice and HIV treatment outcomes: a retrospective cohort study of HIV-infected inmates. Am J Public Health. 2015;105(9):1901–10.CrossRefPubMedPubMedCentral
82.
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5):e38335.CrossRefPubMedPubMedCentral
83.
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend. 2013;132(1–2):378–82.CrossRefPubMedPubMedCentral
84.
Wickersham JA, Marcus R, Kamarulzaman A, Zahari MM, Altice FL. Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ. 2013;91(2):124–9.CrossRefPubMedPubMedCentral
85.
Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, et al. Retention in naltrexone implant treatment for opioid dependence. Drug Alcohol Depend. 2010;111(1):166–9.CrossRefPubMed
86.
Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H. Naltrexone implants compared to methadone: outcomes six months after prison release. Eur Addict Res. 2010;16(3):139–45.CrossRefPubMed
87.
Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.CrossRefPubMedPubMedCentral
88.
Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–54.CrossRefPubMedPubMedCentral
89.
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. The Cochrane Library. 2011;4.
90.
Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet. 2011;377(9776):1468–70.CrossRefPubMed
91.
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39(2):256–68.CrossRefPubMedPubMedCentral
92.
Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav. 2008;35(1):34–47.CrossRefPubMedPubMedCentral
93.
Johnson BT, Eagly AH. Effects of involvement on persuasion: a Meta-analysis. Psychol Bull. 1999;106(2):290–314.CrossRef
94.
Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS Soc. 2013;16(3):1–14.
95.
Livingston JD, Milne T, Fang ML, Amari E. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction. 2012;107(1):39–50.CrossRefPubMedPubMedCentral
96.
Polonsky M, Azbel L, Wickersham JA, Marcus R, Doltu S, Grishaev E, et al. Accessing methadone within Moldovan prisons: prejudice and myths amplified by peers. Int J Drug Policy. 2016;29:91–5.CrossRefPubMed
97.
Epley N, Mak D, Idson LC. Bonus of rebate?: the impact of income framing on spending and saving. J Behav Decis Mak. 2006;19(3):213.CrossRef
Metadaten
Titel
Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators
verfasst von
Maxim Polonsky
Julia Rozanova
Lyuba Azbel
Chethan Bachireddy
Jacob Izenberg
Tetiana Kiriazova
Sergii Dvoryak
Frederick L. Altice
Publikationsdatum
24.03.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 12/2016
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1375-0

Weitere Artikel der Ausgabe 12/2016

AIDS and Behavior 12/2016 Zur Ausgabe

Original Paper

Geographic Variation in Condom Availability and Accessibility

Original Paper

Reasons People Give for Using (or Not Using) Condoms

Original Paper

Partnership-Level Analysis of African American Women’s Risky Sexual Behavior in Main and Non-Main Partnerships

Original Paper

HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States

Original Paper

Prevalence and Correlates of Heterosexual Anal Intercourse Among Men and Women, 20 U.S. Cities

Brief Report

Assessing and Mapping the Availability of the Female Condom in the Philadelphia Metropolitan Area

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise